Trial Profile
A retrospective study to evaluate efficacy of Brentuximab Vedotin in patients with relapsed or refractory Cd30-Positive Hodgkin Lymphoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 19 Dec 2015 New trial record